Urothelial neoplasm

Related records

Broader conditions (11)

• Cancer or benign tumor
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Epithelial neoplasm
• Human disease
• Neoplasm
• Neoplastic disease or syndrome
• Transitional cell neoplasm
• Urinary system disorder
• Urinary system neoplasm

Narrower conditions (46)

• Bladder carcinoma in situ
• Bladder papillary urothelial carcinoma
• Bladder papillary urothelial neoplasm
• Bladder sarcomatoid transitional cell carcinoma
• Bladder transitional cell carcinoma
• Bladder urachal urothelial carcinoma
• Bladder urothelial papilloma
• Infiltrating bladder lymphoepithelioma-like carcinoma
• Infiltrating bladder urothelial carcinoma
• Infiltrating bladder urothelial carcinoma sarcomatoid variant
• Infiltrating bladder urothelial carcinoma, clear cell variant
• Infiltrating renal pelvis transitional cell carcinoma
• Infiltrating renal pelvis/ureter urothelial carcinoma
• Infiltrating ureter transitional cell carcinoma
• Infiltrating urothelial carcinoma
• Inverted urothelial papilloma
• Kidney pelvis sarcomatoid transitional cell carcinoma
• Lipid-cell variant infiltrating bladder urothelial carcinoma
• Lymphoma-like variant infiltrating bladder urothelial carcinoma
• Microcystic variant infiltrating bladder urothelial carcinoma

Trials (122)

• A Comparative Study of Neoadjuvant Chemotherapy Versus Upfront Radical Surgery for Upper Tract Urothelial Carcinoma
• A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
• A Genotype-Phenotype Urothelial Cancer Registry
• A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
• A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
• A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
• A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
• A Phase I Trial of LY3143921 Hydrate in Solid Tumours
• A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma
• A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer
• A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.
• A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
• A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
• A Study of ADRX-0706 in Select Advanced Solid Tumors
• A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma
• A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
• A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
• A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
• A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
• A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer